Lipocine Inc.

News

Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Sep 14, 2026Lipocine Investor Room
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 10, 2026Lipocine Investor Room
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Aug 4, 2026Lipocine Investor Room
Lipocine Appoints Michael J. Grissinger to Board of Directors
Aug 3, 2026Lipocine Investor Room
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Jun 4, 2026Lipocine Investor Room
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
Oct 10, 2024Lipocine
SALT LAKE CITY, Oct. 10, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced positive data from […]
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
Oct 8, 2024Lipocine
SALT LAKE CITY, Oct. 8, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced an exclusive supply […]
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
Oct 2, 2024Lipocine
SALT LAKE CITY, Oct. 2, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will […]
Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
Sep 30, 2024Lipocine
SALT LAKE CITY, Sept. 30, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will present […]
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Sep 5, 2024Lipocine
Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity SALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: […]